UPEC

UPEC Therapeutics is a preclinical-stage biotechnology company dedicated to developing innovative treatments and preventative measures for urinary tract infections (UTIs). The company specifically focuses on addressing infections caused by Uropathogenic Escherichia coli (UPEC), which is the primary pathogen responsible for the majority of community-acquired and recurrent UTIs. By leveraging research into the mechanisms of bacterial adhesion and colonization, UPEC Therapeutics aims to create therapies that prevent the bacteria from establishing a foothold in the bladder. Their approach includes the development of small molecule inhibitors and potential vaccine candidates targeting key bacterial virulence factors. The company's mission is to provide effective alternatives to traditional antibiotics, particularly in the face of rising antimicrobial resistance.